1. Home
  2. PTIX vs ONCO Comparison

PTIX vs ONCO Comparison

Compare PTIX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTIX
  • ONCO
  • Stock Information
  • Founded
  • PTIX 1994
  • ONCO 2018
  • Country
  • PTIX United States
  • ONCO United States
  • Employees
  • PTIX N/A
  • ONCO N/A
  • Industry
  • PTIX Biotechnology: Pharmaceutical Preparations
  • ONCO Biotechnology: Pharmaceutical Preparations
  • Sector
  • PTIX Health Care
  • ONCO Health Care
  • Exchange
  • PTIX Nasdaq
  • ONCO Nasdaq
  • Market Cap
  • PTIX 2.0M
  • ONCO 1.8M
  • IPO Year
  • PTIX 2016
  • ONCO 2022
  • Fundamental
  • Price
  • PTIX $0.22
  • ONCO $0.07
  • Analyst Decision
  • PTIX
  • ONCO
  • Analyst Count
  • PTIX 0
  • ONCO 0
  • Target Price
  • PTIX N/A
  • ONCO N/A
  • AVG Volume (30 Days)
  • PTIX 10.5M
  • ONCO 12.7M
  • Earning Date
  • PTIX 05-14-2025
  • ONCO 05-19-2025
  • Dividend Yield
  • PTIX N/A
  • ONCO N/A
  • EPS Growth
  • PTIX N/A
  • ONCO N/A
  • EPS
  • PTIX N/A
  • ONCO N/A
  • Revenue
  • PTIX N/A
  • ONCO $1,870,605.00
  • Revenue This Year
  • PTIX N/A
  • ONCO N/A
  • Revenue Next Year
  • PTIX N/A
  • ONCO N/A
  • P/E Ratio
  • PTIX N/A
  • ONCO N/A
  • Revenue Growth
  • PTIX N/A
  • ONCO N/A
  • 52 Week Low
  • PTIX $0.18
  • ONCO $0.05
  • 52 Week High
  • PTIX $1.87
  • ONCO $21.40
  • Technical
  • Relative Strength Index (RSI)
  • PTIX 42.85
  • ONCO 31.80
  • Support Level
  • PTIX $0.21
  • ONCO $0.05
  • Resistance Level
  • PTIX $0.25
  • ONCO $0.08
  • Average True Range (ATR)
  • PTIX 0.03
  • ONCO 0.01
  • MACD
  • PTIX -0.01
  • ONCO 0.01
  • Stochastic Oscillator
  • PTIX 9.82
  • ONCO 35.54

About PTIX Protagenic Therapeutics Inc.

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

Share on Social Networks: